Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies

被引:40
|
作者
Lin, Richard J. [1 ]
Elko, Theresa A. [1 ]
Devlin, Sean M. [2 ]
Shahrokni, Armin [3 ,4 ]
Jakubowski, Ann A. [1 ,4 ]
Dahi, Parastoo B. [1 ,4 ]
Perales, Miguel-Angel [1 ,4 ]
Tamari, Roni [1 ,4 ]
Shaffer, Brian C. [1 ,4 ]
Sauter, Craig S. [1 ,4 ]
Papadopoulos, Esperanza B. [1 ,4 ]
Gyurkocza, Boglarka [1 ,4 ]
Korc-Grodzicki, Beatriz [3 ,4 ]
Barker, Juliet N. [1 ,4 ]
Maloy, Molly A. [1 ]
Giralt, Sergio A. [1 ,4 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Adult BMT Serv, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Geriatr Serv, 1275 York Ave, New York, NY 10021 USA
[4] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
ACUTE MYELOID-LEUKEMIA; COMORBIDITY INDEX; RISK-ASSESSMENT; SURVIVAL; AGE; VALIDATION; FERRITIN; ALBUMIN;
D O I
10.1038/s41409-019-0654-6
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Older patients are at increased risk for complications and death following allogeneic hematopoietic cell transplantation (allo-HCT). Traditional transplant-specific prognostic indices such as hematopoietic cell transplant comorbidity index (HCT-CI) may not capture all underlying geriatric vulnerabilities, and in-depth evaluation by a geriatrician prior to transplant may not always be available. We hypothesize that routine pretransplant interdisciplinary clinical assessment may uncover prognostically important geriatric deficits. Using an institutional database of 457 adults aged 60 years and older who underwent first allo-HCT for hematological malignancies from 2010 to 2017, we examined the prognostic impact of pretransplant deficits in geriatric domains of function, mobility, mood, medication, nutrition, and relevant biochemical markers. We found that impairment in instrumental activities of daily living (IADL) was associated with reduced survival through increased nonrelapse mortality (NRM, HR=1.82; 95% CI, 1.04-3.19). The combination of IADL impairment with either HCT-CI/age index or disease risk index readily stratified NRM and overall survival, respectively. In addition, we found that even mild renal dysfunction adversely impacted survival in older transplant patients. Our findings establish important geriatric vulnerabilities in older patients prior to allo-HCT and may provide an entry point for prospective, interventional trials to improve their outcomes.
引用
收藏
页码:157 / 164
页数:8
相关论文
共 50 条
  • [21] Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
    Xiong, Yu
    Bensoussan, Daniele
    Decot, Veronique
    TRANSFUSION MEDICINE REVIEWS, 2015, 29 (04) : 259 - 267
  • [22] Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation (AlloHCT)
    Shah, Nirali
    Borowitz, Michael J.
    Robey, Nancy
    Gamper, Christopher
    Symons, Heather
    Loeb, David
    Wayne, Alan S.
    Chen, Allen
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S306 - S306
  • [23] Clinicopathologic Characteristics Of Secondary Malignancies In Survivors Of Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Hematologic Malignancies
    Chaulagain, Chakra P.
    Kaul, Esha
    Pilichowska, Monika
    Klein, Andreas K.
    Sprague, Kellie
    Miller, Kenneth B.
    BLOOD, 2013, 122 (21)
  • [24] Reply - Letter to the Editor - Impact of route and adequacy of nutritional intake on outcomes of allogeneic hematopoietic cell transplantation for hematologic malignancies
    Beckerson, Julie
    CLINICAL NUTRITION, 2019, 38 (01) : 482 - 482
  • [25] Impact of Obesity on GVHD in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Hematologic Malignancies
    Ardila, Valentina
    Li, Hong
    Brunstein, Claudio
    Kalaycio, Matt
    Sobecks, Ronald
    Sauter, Craig S.
    Hamilton, Betty K.
    TRANSPLANTATION AND CELLULAR THERAPY, 2025, 31 (03): : 178e1 - 178e9
  • [26] Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
    Le, Robert Quan
    Bevans, Margaret
    Savani, Bipin N.
    Mitchell, Sandra A.
    Stringaris, Kate
    Koklanaris, Eleftheria
    Barrett, A. John
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) : 1162 - 1170
  • [27] Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies
    Kim, Inho
    Yoon, Sung Soo
    Lee, Kyung-Hun
    Keam, Bhumsuk
    Kim, Tae Min
    Kim, Jin-Soo
    Kim, Hoon-Gu
    Oh, Myoung-Don
    Han, Kyou-Sup
    Park, Myoung Hee
    Park, Seonyang
    Kim, Byoung Kook
    CLINICAL TRANSPLANTATION, 2006, 20 (04) : 496 - 503
  • [28] Oral mucositis (OM) and outcomes of allogeneic (AL) hematopoietic stem cell transplantation (HSCT) in patients with hematologic malignancies.
    Vera-Lionch, M
    Oster, G
    Ford, C
    Lu, J
    Khazanov, I
    Sonis, S
    BLOOD, 2005, 106 (11) : 874A - 875A
  • [29] Duration of ulcerative mucositis (OM) and outcomes of allogeneic (AL) hematopoietic stem cell transplantation (HSCT) in patients with hematologic malignancies
    Sonis, S
    Vera-Llonch, M
    Ford, C
    Lu, J
    Khazanov, I
    Oster, G
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 23 - 23
  • [30] Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults
    Lin, Richard J.
    Hilden, Patrick D.
    Elko, Theresa A.
    Dahi, Parastoo B.
    Shahrokni, Armin
    Jakubowski, Ann A.
    Perales, Miguel-Angel
    Sauter, Craig S.
    Castro-Malaspina, Hugo R.
    Barker, Juliet N.
    Shaffer, Brian C.
    Tamari, Roni
    Papadopoulos, Esperanza B.
    Maloy, Molly A.
    Korc-Grodzicki, Beatriz
    Giralt, Sergio A.
    BLOOD ADVANCES, 2019, 3 (01) : 12 - 20